1458666-40-4

Upstream product

• 661489-23-2 (2E)-3-(4-amino-3,5-dimethylphenyl)prop-2-enenitrile hydrochloride 
• 116133-09-6 4-[(4,6-dichloro-1,3,5-triazin-2-yl)amino]benzonitrile 
• 873-74-5 4-Aminobenzonitrile 
• 500292-94-4 trans-3-(4-amino-3,5-dimethylphenyl)acrylonitrile 

Downstream Products

• 1452007-75-8 C₂₁H₁₇N₇ 
• 1452006-74-4 (E)-4-((4-((4-(2-cyanovinyl)-2,6-dimethylphenyl)amino)-6-(3-morpholinopropoxy)-1,3,5-triazin-2-yl)amino)benzonitrile 

Relevant academic research and scientific papers

Triazines With Suitable Spacers for Treatment And/Or Prevention of HIV Infections

The present invention relates to the field of HIV-1 infections, and in particular provides novel compounds containing triazine rings and suitable spacers. The compounds according to this invention are very suitable for the prevention and/or treatment of H

TRIAZINES WITH SUITABLE SPACERS FOR TREATMENT AND/OR PREVENTION OF HIV INFECTIONS

The present invention relates to the field of HIV-1 infections, and in particular provides novel compounds containing triazine rings and suitable spacers. The compounds according to this invention are very suitable for the prevention and/or treatment of H

Optimization of diarylazines as anti-HIV agents with dramatically enhanced solubility

Non-nucleoside inhibitors of HIV-1 reverse transcriptase are reported that have ca. 100-fold greater solubility than the structurally related drugs etravirine and rilpivirine, while retaining high anti-viral activity. The solubility enhancements come from strategic placement of a morpholinylalkoxy substituent in the entrance channel of the NNRTI binding site. Compound 4d shows low-nanomolar activity similar to etravirine towards wild-type HIV-1 and key viral variants.